(NASDAQ: LUMO) Lumos Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.81%.
Lumos Pharma's earnings in 2024 is -$35,749,000.On average, 2 Wall Street analysts forecast LUMO's earnings for 2024 to be -$19,050,867, with the lowest LUMO earnings forecast at -$33,471,032, and the highest LUMO earnings forecast at -$4,630,701. On average, 2 Wall Street analysts forecast LUMO's earnings for 2025 to be -$12,754,738, with the lowest LUMO earnings forecast at -$16,410,555, and the highest LUMO earnings forecast at -$9,098,921.
In 2026, LUMO is forecast to generate -$14,704,507 in earnings, with the lowest earnings forecast at -$18,604,045 and the highest earnings forecast at -$10,804,969.